RCT | Riociguat improved hemodynamics but increased dropouts in pulmonary hypertension and HFpEF.

Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial – European Heart Journal

Commentary on Twitter

Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: results of randomized, double-blind, placebo-controlled, multicentre trial out.https://t.co/FYmorikQR5#HFpEF #HF #cardiotwitter @ESC_Journals @escardio pic.twitter.com/4sSeYt7Adq

— EHJ Editor-in-Chief (@ehj_ed) October 7, 2022

Under a https://creativecommons.org/licenses/by-nc/4.0/ license